Nanobots kill off cancerous tumours as fiction becomes reality
A new prospect for cancer treatment opened up last month, when researchers for the first time successfully used tiny, nanometre-sized robots to treat cancerous tumours in mice.
Researchers from Arizona State University and the National Center for Nanoscience and Technology of the Chinese Academy of Sciences injected nanobots made from a folded sheet of DNA into the bloodstream of mice. These targeted the blood vessels around cancerous tumours, injecting them with bloodclotting drugs to cut off their blood supply. According to the study, published in Nature Biotechnology, in February, the treatment was successful in shrinking the tumours and inhibiting their spread.
The idea of armies of minuscule robots patrolling our bodies, cleaning and maintaining them has been a theme in science fiction for decades. The plot of a 1966 film Fantastic Voyage in which a submarine of scientists is shrunk to microscopic size and injected into the blood stream of a colleague in order to help save his life, is now coming closer to reality.
Scientists are exploring the use of nanobots for a number of healthcare uses, not only for fighting cancer, but also to unblock blood vessels in hard to reach areas, taking biopsies or measuring the level of certain chemicals in otherwise inaccessible areas of the body.
A nanobot is a device typically ranging from 0.1-10 micrometres (a micrometre is one millionth of a metre), roughly the size of a red blood cell or smaller. This is too small to add a traditional robotic element like a motor, computer chip or camera, explains Eric Diller, assistant professor, who leads the microrobotics laboratory at the University of Toronto.
Bioengineered bots made from DNA, such as those used in the mouse tumour tests, have been shown to be capable of delivering small doses of drugs with great precision.
A number of hurdles must be overcome, however, before surgical nanorobots will reach clinical trials. Getting the minuscule robots to travel to a precise site in the body and stay there long enough to carry out a procedure is a big challenge, given the speed and frequency of blood flow in the human body.
Nanobots must also avoid being expelled from the body like other toxic or foreign bodies. “Injecting it [the nanobot] into the blood stream and letting itself find the target is pretty much akin to the problem we have with chemotherapy,” says Professor Guang-Zhong Yang, director and founder of the Hamlyn Centre of Robotic Surgery at Imperial College London. Chemotherapy drugs kill both healthy and cancerous cells, so injected nanorobots would need to differentiate between them carefully to surpass this current form of treatment.
It will be easier for the nanobots to operate in parts of the body where blood flow is slower, such as capillaries in the eye or in fluids outside the circulatory system, such as the ventricles of the brain or urinary tract, says Mr Diller.
Ultrasound could be used to propel the nanobots, or, alternatively, bacteria or viruses could be used to carry them to a specific site. Researchers are also exploring ways to use magnetic fields to get the nanobots to reach specific sites and remain in place, against the flow of blood.
Another challenge is tracing nanobots when they are inside the human body, since they are too small to show up on X-rays and other traditional imaging technology. Tracking is essential not only to ensure the nanobots carry out their intended procedures, but also to ensure that the devices, and any tissue they have disrupted, are safely removed.
“This is a serious challenge for our field to overcome. There is no clear answer,” says Mr Diller. Making the nanobot biodegradable is a possible solution, he adds.
Richard Kerr, consultant neurosurgeon and council member of the Royal College of Surgeons of England, chairing its Commission on the Future of Surgery, believes these technical issues will be resolved because of the glut of expertise and research money pouring into the field.
The global nanomedicine market was estimated to be worth $138.8bn in 2016, according to market research company Grand View Research. Making the technology cost effective, however, poses a far greater challenge, he says. “The issues are more about the application of it — how we use it and how we bring it to the clinic within an economical framework.”
With infection, obesity, starvation and diabetes the most pressing global health problems, critics argue that pursuing expensive treatments such as nanobots is not the best use of scarce medical research funds. The cost effectiveness of robotics in surgery is already under scrutiny: a recent study from Stanford University School of Medicine, found that robot-assisted surgery to remove diseased kidneys cost more than traditional surgery and the outcomes were no better.
For nanobots to be successful, they must show that they can exceed the limitations of human surgeons, rather than replicating what they already do, Mr Kerr says. “This technology has to be an aid to surgeons and allow them to do either something they couldn’t before — or it has to do something we were doing before but better,” he says. Precision targeting of cancerous tumors, as seen in the Arizona State University study with mice, could be an case where nanobots can go where a human surgeon’s scalpel cannot reach.
Sarah Shearman is a commissioning editor for Guardian Careers. She is also a freelance journalist covering social issues, sustainability, business and tech.